Bogart Wealth LLC Buys 126,501 Shares of Pfizer Inc. (NYSE:PFE)

Bogart Wealth LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 52.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 366,253 shares of the biopharmaceutical company’s stock after buying an additional 126,501 shares during the quarter. Bogart Wealth LLC’s holdings in Pfizer were worth $9,717,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock worth $3,766,366,000 after acquiring an additional 12,864,343 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Pfizer by 22.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock worth $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Pfizer during the 3rd quarter valued at $146,481,000. Van ECK Associates Corp raised its stake in shares of Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after acquiring an additional 4,726,549 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Pfizer by 164.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company’s stock worth $211,737,000 after purchasing an additional 4,546,809 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.7 %

PFE stock opened at $25.64 on Friday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $145.28 billion, a PE ratio of 18.18, a P/E/G ratio of 0.64 and a beta of 0.64. The firm’s fifty day moving average is $26.28 and its 200 day moving average is $27.63.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the company earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.71%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is currently 121.99%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating and set a $33.00 target price on shares of Pfizer in a research report on Monday. Finally, Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.